Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s State FDA Halts Use of Lethal Tangzhining Capsules

This article was originally published in PharmAsia News

Executive Summary

On receiving China's State FDA report that Tangzhining Capsule manufactured by Guangxi Pingnan Pharmaceutical has caused two deaths, China's Ministry of Health issued an emergency notice on Jan. 30 asking medical institutions to immediately halt its use. MOH wants drugs with the label to be registered and sent for testing. According to reports, two diabetics in Kashi precinct, Xinjiang Uygur Autonomous Region died after taking capsules from the batch. Guangxi FDA's investigations found that Guangxi Pingnan never produced the implicated drugs. After examination, the Institute for Drug Control of Xinjiang Uygur Autonomous Region confirmed that the fake drugs had illicit chemical substance glibenclamide added. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel